news

CUPERTINO, Calif., Aug 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2007. Total revenues were $13.4 million for the three months ended June 30, 2007, compared to $6.1 million for the same period in 2006; revenues in the second quarter […]

CUPERTINO, Calif., July 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2007 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Tuesday, August 7th 2007 at 4:30 p.m. EDT. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) A

Phase IIb Trial Achieves Statistically Significant Reductions in Pain and Total Consumption of Supplemental Opioid Analgesic Medications Versus Placebo CUPERTINO, Calif., July 17 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 122 patient Phase IIb clinical trial of POSIDUR(TM) for treatment of post-operative pain in patients undergoing inguinal hernia repair. This

CUPERTINO, Calif., July 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today reported that patient recruitment has been completed in the pivotal Phase III study with Remoxy(TM), an abuse resistant pain medicine under development based on DURECT’s patented ORADUR(TM) technology incorporating the opioid oxycodone. This event was announced today by Pain Therapeutics, Inc. (Nasdaq: PTIE) and

CUPERTINO, CA, June 27, 2007/ PRNewswire-First Call via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Endo Pharmaceuticals Inc. (Nasdaq: ENDP) has commenced its Phase II clinical program designed to evaluate the conversion of patients being treated with various opioids to sufentanil patches utilizing DURECT’s TRANSDUR™ technology. DURECT had previously announced positive results from

CUPERTINO, Calif., June 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Jefferies Healthcare Conference being held in New York City. Matthew J. Hogan, Chief Financial Officer, will be presenting at the conference on June 27, 2007 at 9:10 AM Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

CUPERTINO, Calif., June 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Sixth Annual Biotechnology and Medical Technology Conference being held at the New York Palace Hotel in New York City. Matthew J. Hogan, Chief Financial Officer, will be presenting at the conference on June 14, 2007 at 2:30

CUPERTINO, Calif., May 17 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Voyager Pharmaceutical has provided its shareholders with an update on its truncated Phase 3 clinical trial for Memryte, an investigational drug for the treatment of Alzheimer’s disease. Voyager has informed its shareholders that they have observed positive outcome trends among women, but

CUPERTINO, Calif., May 8 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it would present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference to be held on May 14-15 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. James E. Brown, President and CEO, will be presenting at

CUPERTINO, Calif., May 7 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2007. Total revenues were $5.7 million for the three months ended March 31, 2007, compared to $5.2 million for the same period in 2006. Net loss for the three months ended March 31, 2007